Photo taken from Armando Orlandi/X
Jan 20, 2025, 13:22
Armando Orlandi: MECCA Trial Highlights Potential in Breast Cancer Treatment
Armando Orlandi, Medical Oncologist, posted the following on X:
“Riding Breast Cancer’s Biggest Data Wave from Literature
Old drugs, new tricks!
MECCA trial reveals metronomic capecitabine could be the OG CDK4/6i alternative, doubling PFS (20.9 vs 11.9 months) in first-line HR+/HER2- mBC.
Cost-effective game-changer?”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 16, 2025, 16:15
Jun 16, 2025, 16:01
Jun 16, 2025, 15:19